Nobuhiko Tamura

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Nihon Medi-Physics Co., Ltd. is a leading manufacturer of radiopharmaceuticals, based in Japan. The Japanese company is engaged in ensuring stable supply and research and development of new products. It is also working on research and development of "theranostics," a novel medical technology to provide optimal medical service to each patient, as well as on the dissemination of nuclear medicine in Asian countries by licensing its products. Nihon Medi-Physics Co. was founded in 1973, and the CEO is Nobuhiko Tamura.

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.

Sunovion Pharmaceuticals Europe Ltd. is a British European pharmaceutical company founded in 2013 that is dedicated to improving the lives of patients through the supply of essential medicines. The company is based in London, UK. The company commercializes and distributes a portfolio of specialty brands and hospital products in 40 countries worldwide, both directly and through strategic partnerships. The company's vision is to become a recognized partner of choice through their commercial excellence, patient focus, and presence across the globe. Sunovion Pharmaceuticals Europe aims to have a positive impact on society through their pioneering focus on their environment, social, and governance (ESG) goals.